Literature DB >> 15472711

Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation.

Malka Nissim-Rafinia1, Micha Aviram, Scott H Randell, Liat Shushi, Efrat Ozeri, Ornit Chiba-Falek, Ofer Eidelman, Harvey B Pollard, James R Yankaskas, Batsheva Kerem.   

Abstract

A significant fraction of disease-causing mutations affects pre-mRNA splicing. These mutations can generate both aberrant and correct transcripts, the level of which varies among different patients. An inverse correlation was found between this level and disease severity, suggesting a role for splicing regulation as a genetic modifier. Overexpression of splicing factors increased the level of correctly spliced RNA, transcribed from minigenes carrying disease-causing splicing mutations. However, whether this increase could restore the protein function was unknown. Here, we demonstrate that overexpression of Htra2-beta1 and SC35 increases the level of normal cystic fibrosis transmembrane conductance regulator (CFTR) transcripts in cystic-fibrosis-derived epithelial cells carrying the 3849+10 kb C --> T splicing mutation. This led to activation of the CFTR channel and restoration of its function. Restoration was also obtained by sodium butyrate, a histone deacetylase inhibitor, known to upregulate the expression of splicing factors. These results highlight the therapeutic potential of splicing modulation for genetic diseases caused by splicing mutations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472711      PMCID: PMC1299168          DOI: 10.1038/sj.embor.7400273

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  29 in total

Review 1.  Splicing regulation as a potential genetic modifier.

Authors:  Malka Nissim-Rafinia; Batsheva Kerem
Journal:  Trends Genet       Date:  2002-03       Impact factor: 11.639

Review 2.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

3.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).

Authors:  Y Hofmann; C L Lorson; S Stamm; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 4.  Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery.

Authors:  M K Mansoura; J Biwersi; M A Ashlock; A S Verkman
Journal:  Hum Gene Ther       Date:  1999-04-10       Impact factor: 5.695

5.  Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides.

Authors:  K J Friedman; J Kole; J A Cohn; M R Knowles; L M Silverman; R Kole
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

6.  Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients.

Authors:  C Andreassi; J Jarecki; J Zhou; D D Coovert; U R Monani; X Chen; M Whitney; B Pollok; M Zhang; E Androphy; A H Burghes
Journal:  Hum Mol Genet       Date:  2001-11-15       Impact factor: 6.150

7.  Treatment of spinal muscular atrophy by sodium butyrate.

Authors:  J G Chang; H M Hsieh-Li; Y J Jong; N M Wang; C H Tsai; H Li
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations.

Authors:  M Nissim-Rafinia; O Chiba-Falek; G Sharon; A Boss; B Kerem
Journal:  Hum Mol Genet       Date:  2000-07-22       Impact factor: 6.150

9.  An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.

Authors:  M L Zhang; C L Lorson; E J Androphy; J Zhou
Journal:  Gene Ther       Date:  2001-10       Impact factor: 5.250

10.  Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis.

Authors:  Anabela S Ramalho; Sebastian Beck; Michelle Meyer; Deborah Penque; Garry R Cutting; Margarida D Amaral
Journal:  Am J Respir Cell Mol Biol       Date:  2002-11       Impact factor: 6.914

View more
  22 in total

1.  Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.

Authors:  Isabel Aznarez; Julian Zielenski; Johanna M Rommens; Benjamin J Blencowe; Lap-Chee Tsui
Journal:  J Med Genet       Date:  2007-05       Impact factor: 6.318

2.  Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis.

Authors:  Laia Masvidal; Susana Igreja; Maria D Ramos; Antoni Alvarez; Javier de Gracia; Anabela Ramalho; Margarida D Amaral; Sara Larriba; Teresa Casals
Journal:  Eur J Hum Genet       Date:  2013-10-16       Impact factor: 4.246

3.  Sodium Butyrate and Valproic Acid as Splicing Restoring Agents in Erythroid Cells of β-Thalassemic Patients.

Authors:  Mahmoud Shekari Khaniani; Mahdieh Tagizadeh; Abbasali Hosseinpour Feizi; Sima Mansoori Derakhshan
Journal:  Iran J Biotechnol       Date:  2016-03       Impact factor: 1.671

4.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

5.  Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells.

Authors:  J Ciura; P P Jagodziński
Journal:  Mol Biol Rep       Date:  2010-03-07       Impact factor: 2.316

6.  Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal.

Authors:  Talia M Mota; Chase D McCann; Ali Danesh; Szu-Han Huang; Dean B Magat; Yanqin Ren; Louise Leyre; Tracy D Bui; Thomas M Rohwetter; Colin M Kovacs; Erika Benko; Lynsay MacLaren; Avery Wimpelberg; Christopher M Cannon; W David Hardy; Jeffrey T Safrit; R Brad Jones
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

7.  Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment.

Authors:  Eva Pros; Juana Fernández-Rodríguez; Llúcia Benito; Anna Ravella; Gabriel Capellá; Ignacio Blanco; Eduard Serra; Conxi Lázaro
Journal:  Eur J Hum Genet       Date:  2009-11-25       Impact factor: 4.246

8.  A targeted deleterious allele of the splicing factor SCNM1 in the mouse.

Authors:  Viive M Howell; Georgius de Haan; Sarah Bergren; Julie M Jones; Cymbeline T Culiat; Edward J Michaud; Wayne N Frankel; Miriam H Meisler
Journal:  Genetics       Date:  2008-09-14       Impact factor: 4.562

9.  Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing.

Authors:  Marco Baralle; Tibor Pastor; Erica Bussani; Franco Pagani
Journal:  Am J Hum Genet       Date:  2008-07       Impact factor: 11.025

10.  Novel human bronchial epithelial cell lines for cystic fibrosis research.

Authors:  M L Fulcher; S E Gabriel; J C Olsen; J R Tatreau; M Gentzsch; E Livanos; M T Saavedra; P Salmon; S H Randell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-31       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.